RPL34B Antibody

What is RPL34 and what is its function in cellular processes?

RPL34 belongs to the L34E family of ribosomal proteins and contains a distinctive zinc finger motif. It functions as a crucial component of the 60S large ribosomal subunit. The primary role of RPL34 is participating in the ribonucleoprotein complex responsible for protein synthesis within cells . Recent research has revealed that beyond its canonical function in translation, RPL34 may play important roles in cellular proliferation, migration, and invasion, particularly in cancer contexts . The protein has been found to be frequently upregulated in various human malignancies, including esophageal cancer, non-small cell lung cancer, gastric cancer, and pancreatic cancer .

What are the key applications for RPL34 antibodies in research?

RPL34 antibodies can be utilized in multiple experimental applications, with the most common being:

• Western Blotting (WB): For detecting and quantifying RPL34 protein expression in cell or tissue lysates

• Immunohistochemistry (IHC-P): For visualizing RPL34 distribution in paraffin-embedded tissue sections

• Immunocytochemistry/Immunofluorescence (ICC/IF): For determining subcellular localization of RPL34 in cultured cells

Studies utilizing these techniques have demonstrated that RPL34 typically shows positivity in both nucleoli and cytoplasm of cells, consistent with its role in ribosome assembly and function .

How should I select an appropriate RPL34 antibody for my research?

When selecting an RPL34 antibody, consider the following factors:

• Host Species: Most commercial RPL34 antibodies are rabbit polyclonal antibodies, which offers good sensitivity but may have batch-to-batch variation

• Target Region: Confirm the immunogen used for antibody production - many target within the first 100 amino acids of human RPL34

• Validated Applications: Choose antibodies specifically validated for your intended application (WB, IHC, ICC/IF)

• Species Cross-Reactivity: While most are optimized for human samples, some may work with other species based on sequence homology

The table below summarizes top validated commercial RPL34 antibodies:

What are the recommended protocols for using RPL34 antibodies in immunofluorescence?

For optimal immunofluorescence results with RPL34 antibodies, follow this methodological approach:

• Cell Preparation: Fix cells with PFA (paraformaldehyde) and permeabilize with Triton X-100 to allow antibody access to intracellular compartments

• Antibody Concentration: Use RPL34 antibodies at 1-4 μg/ml concentration for optimal signal-to-noise ratio in immunofluorescence applications

• Expected Localization: Look for positive staining in both nucleoli and cytoplasm, which is the characteristic localization pattern for RPL34

• Controls: Always include negative controls (omitting primary antibody) and positive controls (cell lines known to express RPL34, such as U-2 OS cells)

How can I design and validate RPL34 knockdown experiments?

For effective RPL34 knockdown studies, implement the following methodology:

• shRNA Design: Design short hairpin RNAs (shRNAs) specifically targeting the RPL34 mRNA sequence. Commercial vendors such as GeneChem have successfully designed effective RPL34-targeting shRNAs

• Transfection Method: Use lipid-based transfection reagents like Lipofectamine 2000 for introducing shRNA constructs into cells

• Validation Timeline: Assess knockdown efficiency at 48 hours post-transfection, which has been shown to be effective for RPL34

• Validation Methods: Confirm knockdown through both:

  • qRT-PCR to measure mRNA reduction

  • Western blot to verify protein reduction

• Negative Control: Always include a non-targeting shRNA (sh-NC) as a critical experimental control

This approach has successfully achieved significant downregulation of RPL34 at both mRNA and protein levels in cancer cell lines, enabling functional studies .

What is the role of RPL34 in cancer progression and how can antibodies help investigate this?

RPL34 has emerged as a potential oncogene in multiple cancers. Research using RPL34 antibodies has revealed:

• Expression Pattern: RPL34 is frequently upregulated in esophageal cancer, non-small cell lung cancer, gastric cancer, and pancreatic cancer cell lines compared to normal cells

• Functional Impact: Knockdown studies show that depleting RPL34 inhibits:

  • Cell proliferation (in a time-dependent manner)

  • Invasion capacity

  • Migration ability

  • Tumor growth in vivo

• Molecular Mechanisms: RPL34 appears to regulate epithelial-mesenchymal transition (EMT) markers, with knockdown resulting in:

  • Upregulation of E-cadherin (epithelial marker)

  • Downregulation of N-cadherin (mesenchymal marker)

RPL34 antibodies are critical tools for investigating these relationships through Western blot analysis of RPL34 and associated proteins in different cellular contexts .

How does RPL34 interact with the PI3K/Akt signaling pathway?

RPL34 appears to functionally interact with the PI3K/Akt pathway, which is crucial for understanding its role in cancer biology:

• Pathway Interaction: Knockdown of RPL34 significantly downregulates phosphorylated PI3K (p-PI3K) and phosphorylated Akt (p-Akt) protein levels in cancer cells

• Functional Validation: PI3K inhibitor (LY294002) treatment produces similar effects to RPL34 knockdown:

  • Decreased cell viability

  • Suppressed cell proliferation

  • Inhibited invasion capacity

• Mechanistic Significance: This interaction provides a potential mechanism by which RPL34 promotes cancer progression, as the PI3K/Akt pathway is constitutively activated in esophageal tumors and regulates cell proliferation, angiogenesis, invasion, and metastasis

To investigate this interaction, researchers can use RPL34 antibodies in combination with antibodies against p-PI3K and p-Akt in Western blot analyses following RPL34 knockdown or overexpression .

What are the methodological considerations when using RPL34 antibodies for immunohistochemistry?

When conducting immunohistochemistry (IHC) with RPL34 antibodies, consider these methodological details:

• Tissue Preparation: Use paraffin-embedded tissue sections with appropriate antigen retrieval methods

• Antibody Dilution: For optimal staining, a 1/10 dilution of RPL34 antibody (such as ab122255) has been demonstrated to be effective in human pancreatic tissue

• Expected Staining Pattern: RPL34 staining should be observed in both cytoplasmic and nucleolar compartments of cells

• Tissue Selection: Based on current research, pancreatic tissue has been successfully used for RPL34 IHC studies, showing clear staining patterns

• Controls: Include positive control tissues (such as pancreas) and negative controls (primary antibody omitted) in each experimental run

How can I validate the specificity of RPL34 antibodies in my experimental system?

Ensuring antibody specificity is critical for reliable results. Implement these validation approaches:

• Western Blot Validation:

  • Expect a single band at the predicted molecular weight of RPL34 (approximately 13 kDa)

  • Use molecular weight markers to confirm size accuracy (15-25 kDa range)

  • Compare pattern with published literature

• Knockdown Controls:

  • Perform Western blot on samples from RPL34 knockdown cells

  • Observe decreased or absent signal in knockdown samples compared to controls

• Competitive Blocking:

  • Pre-incubate antibody with recombinant RPL34 protein

  • Observe elimination or significant reduction of signal

• Multiple Antibody Validation:

  • Use multiple antibodies targeting different epitopes of RPL34

  • Observe consistent staining patterns across antibodies

• Immunoprecipitation:

  • Perform IP with RPL34 antibody followed by mass spectrometry

  • Confirm capture of RPL34 and known interacting partners

What are common issues encountered with RPL34 antibodies and how can they be resolved?

Several technical challenges may arise when working with RPL34 antibodies:

• High Background in Immunofluorescence:

  • Solution: Optimize antibody concentration (1-4 μg/ml recommended)

  • Increase blocking time and use more stringent washing

  • Treat cells with PFA/Triton X-100 for optimal permeabilization

• Weak Western Blot Signal:

  • Solution: Adjust protein loading (RPL34 is moderately abundant in most cell types)

  • Optimize transfer conditions for small proteins (13 kDa)

  • Increase primary antibody concentration or incubation time

• Inconsistent Knockdown Results:

  • Solution: Validate knockdown efficiency at both mRNA and protein levels

  • Wait 48 hours post-transfection before analysis, as this timepoint has been established as effective

  • Test multiple shRNA sequences if initial attempts show poor knockdown

How can I optimize RPL34 antibody use for studying cancer tissues?

For cancer tissue studies, consider these specialized approaches:

• Comparative Analysis:

  • Always include matched normal tissue controls when examining cancer samples

  • RPL34 is typically upregulated in malignant tissues compared to normal counterparts

• Correlation with Clinical Parameters:

  • Document clinical information (tumor stage, grade, patient outcome) to correlate with RPL34 expression

  • Research suggests RPL34 expression may have prognostic significance in multiple cancer types

• Multiplexed Analysis:

  • Co-stain with markers of PI3K/Akt pathway activation (p-PI3K, p-Akt)

  • Include EMT markers (E-cadherin, N-cadherin) to investigate relationship with RPL34 expression